Publication & Citation Trends
Publications
0 total
Abstract CT034: GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors
Cited by 10
Semantic Scholar
Hallmarks of Resistance to Immune-Checkpoint Inhibitors OA
Cited by 97
Semantic Scholar
171P Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX: A multitumor study of a subcutaneous (SC) formulation of nivolumab (NIVO) monotherapy
Cited by 2
Semantic Scholar
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
Cited by 209
Semantic Scholar
Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade
Cited by 0
Semantic Scholar
Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma OA
Cited by 48
Semantic Scholar
Metabolomic adaptations and correlates of survival to immune checkpoint blockade OA
Cited by 200
Semantic Scholar
Abstract P4-06-07: Activity of nivolumab alone or in combination with targeted therapies in a humanized BLT-mouse model of human breast cancer
Cited by 0
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(65)
CAR-T cell therapy research
(47)
Mechanisms of cancer metastasis
(27)
Immunotherapy and Immune Responses
(26)
Cancer Treatment and Pharmacology
(21)
Affiliations
Broad Institute
Ontario Institute for Cancer Research
Tufts University
Novartis (Switzerland)
National Institutes of Health